Trials
2 active
3 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Alzheimer Disease
- Main trialPhase 1
- “This study is a Phase I, single-center, randomized, open-label, parallel-controlled study, aimed at evaluating the pharmacokinetics, pharmacodynamics, immunogenicity, safety, and tolerability of a single dose of CM383 administered via intravenous infusion or subcutaneous injection in healthy male subjects.”In the company’s words, NCT07292688 on ClinicalTrials.gov
- Other names
- Alzheimer Disease
Other drugs for Alzheimer Disease
- Xanomeline/Trospium ChlorideBristol Myers Squibb · Phase 3
- -APN-1607JYAMS PET Research & Development Limited · Phase 3
- LecanemabEisai · Biogen · Phase 3
- DMB-IBigespas LTD · Phase 3
- TrontinemabRoche · Phase 3
- Buntanetap/posiphenAnnovis Bio Inc. · Phase 3
Coming up1
- 30 DecPhase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | Jul 2026 | Study of CM383 in Healthy Subjects | |
| Phase 1Recruiting | 30 Dec 2026 | A Study of CM383 in Patients With Alzheimer's Disease Related Mild Cognitive Impairment and Mild Alzheimer's Disease | |
| Phase 1Unknown | 30 Jun 2025 | Single Dose Escalation Study of CM383 in Healthy Volunteers |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026